Galectin Therapeutics publishes belapectin trial results in Hepatology

May 11, 2026 8:00 AM

Galectin Therapeutics Inc. (NASDAQ: GALT) announced the publication of results from its NAVIGATE Phase 2b clinical trial in the Journal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found